blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3697449

EP3697449 - TREATMENT OF OCULAR DISEASES AND METASTATIC COLON CANCER WITH HUMAN POST-TRANSLATIONALLY MODIFIED VEGF-TRAP [Right-click to bookmark this link]
StatusExamination is in progress
Status updated on  17.02.2023
Database last updated on 14.09.2024
FormerRequest for examination was made
Status updated on  24.07.2020
FormerThe international publication has been made
Status updated on  26.04.2019
Formerunknown
Status updated on  21.11.2018
Most recent event   Tooltip14.10.2023New entry: Renewal fee paid 
Applicant(s)For all designated states
REGENXBIO Inc.
9600 Blackwell Road
Suite 210
Rockville, MD 20850 / US
[2020/35]
Inventor(s)01 / DANOS, Olivier
1349 Lexington Ave., Apt. 4G
New York NY 10128 / US
02 / WU, Zhuchun
14716 Soft Wind Dr.
North Potomac MD 20878 / US
03 / GERNER, Franz
3546 Brethren Church Road
Myersville MD 21773 / US
04 / VAN EVEREN, Sherri
823 Paulson Circle
Menlo Park CA 94025 / US
 [2020/35]
Representative(s)Appleyard Lees IP LLP
15 Clare Road
Halifax HX1 2HY / GB
[2020/35]
Application number, filing date18800376.817.10.2018
[2020/35]
WO2018US56343
Priority number, dateUS201762574038P18.10.2017         Original published format: US 201762574038 P
[2020/35]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2019079494
Date:25.04.2019
Language:EN
[2019/17]
Type: A1 Application with search report 
No.:EP3697449
Date:26.08.2020
Language:EN
The application published by WIPO in one of the EPO official languages on 25.04.2019 takes the place of the publication of the European patent application.
[2020/35]
Search report(s)International search report - published on:EP25.04.2019
ClassificationIPC:A61K48/00, C12N15/85, C12N15/864, A61K38/17, C07K14/475
[2020/35]
CPC:
C12N15/86 (EP,US); A61K38/179 (EP); A61K48/0058 (EP);
A61K9/0019 (US); A61K9/0048 (US); A61K9/0051 (US);
C07K14/475 (EP); C07K14/71 (US); C12N7/00 (US);
A61K35/761 (EP); A61K38/00 (US); A61K48/00 (US);
A61K48/0075 (EP); C07K2319/02 (US); C07K2319/30 (US);
C07K2319/33 (US); C07K2319/90 (US); C12N2750/14143 (EP,US);
C12N2750/14151 (US); C12N2800/22 (EP,US); C12N2830/002 (US);
C12N2830/50 (US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2020/35]
Extension statesBA18.05.2020
ME18.05.2020
TitleGerman:BEHANDLUNG VON AUGENKRANKHEITEN UND METASTASIERENDEM DICKDARMKREBS MIT MENSCHLICHER POST-TRANSLATIONAL MODIFIZIERTER VEGF-FALLE[2020/35]
English:TREATMENT OF OCULAR DISEASES AND METASTATIC COLON CANCER WITH HUMAN POST-TRANSLATIONALLY MODIFIED VEGF-TRAP[2020/35]
French:TRAITEMENT DE MALADIES OCULAIRES ET D'UN CANCER DU CÔLON MÉTASTATIQUE AVEC UN PIÈGE À VEGF AVEC MODIFICATION POST-TRADUCTIONNELLE HUMAIN[2020/35]
Entry into regional phase18.05.2020National basic fee paid 
18.05.2020Designation fee(s) paid 
18.05.2020Examination fee paid 
Examination procedure18.05.2020Examination requested  [2020/35]
18.05.2020Date on which the examining division has become responsible
22.12.2020Amendment by applicant (claims and/or description)
16.02.2023Despatch of a communication from the examining division (Time limit: M06)
25.08.2023Reply to a communication from the examining division
Fees paidRenewal fee
18.05.2020Renewal fee patent year 03
08.10.2021Renewal fee patent year 04
12.10.2022Renewal fee patent year 05
13.10.2023Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[A]CN103304668  (JIANGSU JIANDE BIOLOG PHARMACEUTICAL CO LTD) [A] 28 * example 3 *;
 [XP]WO2018160686  (ADVERUM BIOTECHNOLOGIES INC [US]) [XP] 1-8,19-26* paragraphs [0009] , [0182]; claims 1,17 *;
 [XY]  - HARDING ET AL, "AAV Serotype 8-Mediated Gene Delivery of a Soluble VEGF Receptor to the CNS for the Treatment of Glioblastoma", MOLECULAR THERAPY : THE JOURNAL OF THE AMERICAN SOCIETY OF GENE THERAPY, ACADEMIC PRESS ; NATURE PUBLISHING GROUP, US, (20060501), vol. 13, no. 5, doi:10.1016/J.YMTHE.2006.02.004, ISSN 1525-0016, pages 956 - 966, XP005416312 [X] 1-4,27 * page 957, column r, lines 7-10; figure 1 * [Y] 7,8,21-26,29

DOI:   http://dx.doi.org/10.1016/j.ymthe.2006.02.004
 [I]  - NICHOLAS A. MOORE ET AL, "Gene therapy for age-related macular degeneration", EXPERT OPINION ON BIOLOGICAL THERAPY, ASHLEY, LONDON; GB, (20170720), vol. 17, no. 10, doi:10.1080/14712598.2017.1356817, ISSN 1471-2598, pages 1235 - 1244, XP055404429 [I] 5,6,19,20,23 * page 1239, column l, paragraph 3 * * page 1239, column r, paragraph 2 *

DOI:   http://dx.doi.org/10.1080/14712598.2017.1356817
 [I]  - JENNIFER DUMONT ET AL, "Human cell lines for biopharmaceutical manufacturing: history, status, and future perspectives", CRC CRITICAL REVIEWS IN BIOTECHNOLOGY, US, (20150918), vol. 36, no. 6, doi:10.3109/07388551.2015.1084266, ISSN 0738-8551, pages 1110 - 1122, XP055532666 [I] 9-18,28 * abstract *

DOI:   http://dx.doi.org/10.3109/07388551.2015.1084266
 [A]  - JEFFREY S. HEIER ET AL, "Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular Degeneration", OPHTHALMOLOGY, (20121201), vol. 119, no. 12, doi:10.1016/j.ophtha.2012.09.006, ISSN 0161-6420, pages 2537 - 2548, XP055138976 [A] 1-28 * abstract *

DOI:   http://dx.doi.org/10.1016/j.ophtha.2012.09.006
 [Y]  - TZU-FEI WANG ET AL, "Aflibercept in the Treatment of Metastatic Colorectal Cancer", CLINICAL MEDICINE INSIGHTS: ONCOLOGY, NZL, (20120101), vol. 6, doi:10.4137/CMO.S7432, ISSN 1179-5549, XP055533035 [Y] 7,8,21-26 * abstract *

DOI:   http://dx.doi.org/10.4137/CMO.S7432
 [Y]  - MARTIN LOCK ET AL, "Rapid, Simple, and Versatile Manufacturing of Recombinant Adeno-Associated Viral Vectors at Scale", HUMAN GENE THERAPY, US, (20101001), vol. 21, no. 10, doi:10.1089/hum.2010.055, ISSN 1043-0342, pages 1259 - 1271, XP055533316 [Y] 29 * page 1260, column r, paragraph l - page 1261, column l, paragraph 1 *

DOI:   http://dx.doi.org/10.1089/hum.2010.055
 [A]  - Deniz Dalkara ET AL, "In vivo-directed evolution of a new adeno-associated virus for therapeutic outer retinal gene delivery from the vitreous", Science translational medicine, United States, doi:10.1126/scitranslmed.3005708, (20130612), pages 189ra76 - 189ra76, URL: http://stm.sciencemag.org/content/scitransmed/5/189/189ra76.full.pdf, (20181212), XP055533378 [A] 6 * page 2 *

DOI:   http://dx.doi.org/10.1126/scitranslmed.3005708
 [A]  - MINH NGUYEN ET AL, "Rapamycin-regulated Control of Antiangiogenic Tumor Therapy Following rAAV-mediated Gene Transfer", MOLECULAR THERAPY : THE JOURNAL OF THE AMERICAN SOCIETY OF GENE THERAPY, US, (20070501), vol. 15, no. 5, doi:10.1038/mt.sj.6300079, ISSN 1525-0016, pages 912 - 920, XP055233214 [A] 1 * abstract *

DOI:   http://dx.doi.org/10.1038/mt.sj.6300079
 [A]  - IGARASHI TSUTOMO ET AL, "Adeno-Associated Vector (Type 8) Mediated Expression of Flt-1 Efficiently Inhibits Neovascularization in a Murine Choroidal Neovascularization Model", Molecular Therapy, vol. 17, no. Supplement 1, ISSN 1525-0016, (20090501), Database accession no. 751, page S287, MOLECULAR THERAPY : THE JOURNAL OF THE AMERICAN SOCIETY OF GENE THERAPY, ACADEMIC PRESS ; NATURE PUBLISHING GROUP, US, URL: http://www.cell.com/molecular-therapy-family/molecular-therapy/pdf/S1525-0016%2816%2939111-0.pdf, (20181212), XP008183816 [A] 5,6,23 * abstract *
by applicantWO9418317
 WO9620951
 WO9641865
 WO9910508
 WO9910510
 WO9936553
 WO9941258
 US6596535
 US7067526
 US7125717
 US7282199
 US7456683
 US7790449
 US7906111
 US8318480
 US2013224836
 US8524446
 US8628966
 US8734809
 US8927514
 US8962332
 US8999678
 US2015126588
 US9169299
 US9193956
 US2015374803
 US9284357
 US2016215024
 US9409953
 US9458517
 US2016376323
 US2017051257
 US9587282
 US9585971
 US2017067908
 WO2018075798
    - MITCHELL; BRADLEY, Health Qual Life Outcomes, (20060000), vol. 4, page 97
    - BROWN, N Engl J Med, (20060000), vol. 355, pages 1432 - 1444
    - ROSENFELD, N Engl J Med, (20060000), vol. 355, pages 1419 - 1431
    - SCHMIDT-ERFURTH, Ophthalmology, (20140000), vol. 121, no. 1, pages 193 - 201
    - BENDER et al., Clin. Cancer Res., (20120000), vol. 18, page 5081
    - SCHODEL et al., Blood, (20110000), vol. 117, no. 23, pages e207 - e217
    - KENNETH; ROCHA, Biochem J., (20080000), vol. 414, pages 19 - 29
    - TSUCHIYA, J. Biochem., (19930000), vol. 113, page 395
    - SALVI, Biochemistry and Biophysics Reports, (20170000), vol. 9, pages 13 - 21
    - POWELL; RIVERA-SOTO, Discov. Med., (20150000), vol. 19, no. 102, pages 49 - 57
    - QUAX et al., Mol Cell, (20150000), vol. 59, pages 149 - 161
    - ANDERSEN, J Biol Chem, (20120000), vol. 287, pages 22927 - 22937
    - CHEN, "Fusion protein linkers: property, design and functionality", Adv. Drug. Deliv., (20130000), vol. 65, no. 10, doi:doi:10.1016/j.addr.2012.09.039, pages 1357 - 1369, XP028737352

DOI:   http://dx.doi.org/10.1016/j.addr.2012.09.039
    - AVERY et al., Retina, the Journal of Retinal and Vitreous Diseases, (20170000), vol. 0, pages 1 - 12
    - AVERY et al., Br J Ophthalmol, (20140000), vol. 98, pages 1636 - 1641
    - WANG et al., Analytical Biochem., (20130000), vol. 427, pages 20 - 28
    - ADAMIS et al., BBRC, (19930000), vol. 193, pages 631 - 638
    - KANAN et al., Exp. Eye Res., (20090000), vol. 89, pages 559 - 567
    - KANAN; AL-UBAIDI, Exp. Eye Res., (20150000), vol. 133, pages 126 - 131
    - CLERC et al., Glycoconj, (20160000), vol. 33, pages 309 - 343
    - POMPACH et al., J Proteome Res., (20140000), vol. 13, pages 5561 - 5569
    - E MISHIRO, J Biochem, (20060000), vol. 140, pages 731 - 737
    - BOVENKAMP et al., J. Immunol., (20160000), vol. 196, pages 1435 - 1441
    - DUMONT et al., Critical Rev in Biotech, (20150000), vol. 36, no. 6, pages 1110 - 1122
    - BOSQUES, Nat Biotech, (20100000), vol. 28, pages 1153 - 1156
    - YANG et al., Molecules, (20150000), vol. 20, pages 2138 - 2164
    - LOOS et al., PNAS, (20150000), vol. 112, pages 12675 - 12680
    - CHOE et al., Cell, (20030000), vol. 114, pages 161 - 170
    - MIKKELSEN; EZBAN, Biochemistry, (19910000), vol. 30, pages 1533 - 1537
    - FARID-MOAYER et al., J. Bacteriol., (20070000), vol. 189, pages 8088 - 8098
    - DUMONT et al., "Human cell lines for biopharmaceutical manufacturing: history, status, and future perspectives", Critical Rev in Biotech, (20150000), vol. 36, no. 6, doi:doi:10.3109/07388551.2015.1084266, pages 1110 - 1122, XP055333163

DOI:   http://dx.doi.org/10.3109/07388551.2015.1084266
    - SCHUMAN, Trans. Am. Opthalmol. Soc., (20080000), vol. 106, pages 426 - 458
    - HOLASH et al., Proc. Natl. Acad. Sci. USA., (20020000), vol. 99, no. 17, page 11393
    - DE OLIVEIRA DIAS et al., Int J Retin Vitr, (20160000), vol. 2, page 3
    - QUAX et al., Mol. Cell, (20150000), vol. 59, pages 149 - 161
    - DING et al., MAbs, (20170000), vol. 9, pages 269 - 284
    - KIM, Eur J Immunol, (19990000), vol. 29, page 2819
    - REGULA, EMBO Mol Med, (20160000), vol. 8, pages 1265 - 1288
    - VAN DEN BREMER et al., mAbs, (20150000), vol. 7, pages 672 - 680
    - HU et al., Biotechnol. Prog., (20170000), vol. 33, pages 786 - 794
    - HANSSON et al., J. Biol. Chem., (20150000), vol. 290, no. 9, pages 5661 - 5672
    - ZINN et al., Cell Rep., (20150000), vol. 12, no. 6, pages 1056 - 1068
    - WU, Human Gene Therapy, (20070000), vol. 18, no. 2, pages 171 - 182
    - MCCARTY et al., Gene Therapy, (20010000), vol. 8, no. 16, pages 1248 - 1254
    - ALBA et al., "Gutless adenovirus: last generation adenovirus for gene therapy", Gene Therapy, (20050000), vol. 12, doi:doi:10.1038/sj.gt.3302612, pages S18 - S27, XP008102765

DOI:   http://dx.doi.org/10.1038/sj.gt.3302612
    - LESCH et al., "Production and purification of lentiviral vector generated in 293T suspension cells with baculoviral vectors", Gene Therapy, (20110000), vol. 18, doi:doi:10.1038/gt.2010.162, pages 531 - 538, XP055339732

DOI:   http://dx.doi.org/10.1038/gt.2010.162
    - AUSUBEL et al., "Production of CGMP-Grade Lentiviral Vectors", Bioprocess Int., (20120000), vol. 10, no. 2, pages 32 - 43, XP055324289
    - DINCULESCU et al., Hum Gene Ther, (20050000), vol. 16, pages 649 - 663
    - TSUCHIYA et al., J. Biochem., (19930000), vol. 113, pages 395 - 400
    - STERN et al., Trends Cell. Mol. Biol., (20070000), vol. 2, pages 1 - 17
    - DALTON; BARTON, Protein Sci, (20140000), vol. 23, pages 517 - 525
    - GURTU et al., Biochem. Biophys. Res. Comm., (19960000), vol. 229, no. 1, pages 295 - 298
    - FURLING et al., Gene Ther, (20010000), vol. 8, no. 11, pages 854 - 873
    - FANG et al., Nature Biotechnology, (20050000), vol. 23, pages 584 - 590
    - FANG, Mol Ther, (20070000), vol. 15, pages 1153 - 1159
    - FANG et al., Molecular Therapy, (20070000), vol. 15, no. 6, pages 1153 - 1159
    - LUKE, Innovations in Biotechnology, (20120000), pages 161 - 186
    - YAN et al., J. Virol., (20050000), vol. 79, no. 1, pages 364 - 379
    - APONTE-UBILLUS et al., Appl. Microbiol. Biotechnol., (20180000), vol. 102, pages 1045 - 1054
    - ROHRER, J.S., "Analyzing Sialic Acids Using High-Performance Anion-Exchange Chromatography with Pulsed Amperometric Detection", Anal. Biochem., (20000000), vol. 283, pages 3 - 9
    - HARA et al., "Highly Sensitive Determination of N-Acetyl-and N-Glycolylneuraminic Acids in Human Serum and Urine and Rat Serum by Reversed-Phase Liquid Chromatography with Fluorescence Detection", J. Chromatogr., B: Biomed., (19890000), vol. 377, doi:doi:10.1016/S0378-4347(00)80766-5, pages 111 - 119, XP026513701

DOI:   http://dx.doi.org/10.1016/S0378-4347(00)80766-5
    - GALILI et al., "A sensitive assay for measuring alpha-Gal epitope expression on cells by a monoclonal anti-Gal antibody", Transplantation, (19980000), vol. 65, no. 8, doi:doi:10.1097/00007890-199804270-00020, pages 1129 - 1132, XP001097939

DOI:   http://dx.doi.org/10.1097/00007890-199804270-00020
    - AYOUB et al., "Correct primary structure assessment and extensive glyco-profiling of cetuximab by a combination of intact, middle-up, middle-down and bottom-up ESI and MALDI mass spectrometry techniques", Landes Bioscience, (20130000), vol. 5, no. 5, doi:doi:10.4161/mabs.25423, pages 699 - 710, XP055102410

DOI:   http://dx.doi.org/10.4161/mabs.25423
    - PLATTS-MILLS et al., "Anaphylaxis to the Carbohydrate Side-Chain Alpha-gal", Immunol Allergy Clin North Am., (20150000), vol. 35, no. 2, pages 247 - 260
    - SONG et al., Anal. Chem., (20140000), vol. 86, pages 5661 - 5666
    - CAMPOCHIARO et al., Hum Gen Ther, (20160926), URL: doi: 10.1089/hum.2016.117
    - PATEL et al., Invest Ophth & Vis Sci, (20120000), vol. 53, pages 4433 - 4441
    - PATEL et al., Pharm Res, (20110000), vol. 28, pages 166 - 176
    - OLSEN, Am J Ophth, (20060000), vol. 142, pages 777 - 787
    - SCHUMAN, Trans. Am. Opthamol. Soc., (20080000), vol. 106, pages 426 - 458
 WO2014EP76466
 WO2015EP53335
 WO2015US34799
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.